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The basis for strong immunogenetic associations
between particular human leukocyte antigen (HLA)
class I allotypes and inflammatory conditions likeBeh-
c¸et’s disease (HLA-B51) and ankylosing spondylitis
(HLA-B27) remain mysterious. Recently, however,
even stronger HLA associations are reported in drug
hypersensitivities to the reverse-transcriptase inhibi-
tor abacavir (HLA-B57), the gout prophylactic allopuri-
nol (HLA-B58), and the antiepileptic carbamazepine
(HLA-B*1502), providing a defined disease trigger
and suggesting a general mechanism for these
associations. We show that systemic reactions to
abacavir were driven by drug-specific activation of
cytokine-producing, cytotoxic CD8+ T cells. Recogni-
tion of abacavir required the transporter associated
with antigen presentation and tapasin, was fixation
sensitive, and was uniquely restricted by HLA-B*5701
and not closely related HLA allotypes with polymor-
phisms in the antigen-binding cleft. Hence, the strong
association of HLA-B*5701 with abacavir hypersensi-
tivity reflects specificity through creation of a unique li-
gand as well as HLA-restricted antigen presentation,
suggesting a basis for the strong HLA class I-associa-
tion with certain inflammatory disorders.
INTRODUCTION
Polymorphic human leukocyte antigen (HLA) class I molecules
present pathogen-derived peptides to killer T cells mediating822 Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc.protective immunity (Margulies et al., 2008). However particular
major histocompatibility complex-I (MHC-I) allotypes are much
more strongly associated with inflammatory, autoimmune-like
diseases than they are with protective immunity phenotypes in
infectious disease (Margulies et al., 2008). The reason for this
paradox is unclear, and the mechanisms by which certain
MHC-I allotypes are associated with inflammatory diseases
like ankylosing spondylitis, Behc¸et’s disease, and birdshot reti-
nopathy are not understood (Margulies et al., 2008). Recently,
however, hypersensitivity to the reverse-transcriptase inhibitor
abacavir has been strongly associated with HLA-B*5701 (He-
therington et al., 2002; Mallal et al., 2002; Martin et al., 2004),
providing an opportunity to unravel the mechanism of at least
this MHC-I disease association with the potential to understand
other MHC-I associations. Multiorgan reactions to abacavir
occur in approximately 2%–8% of patients with human immuno-
deficiency virus-I (HIV-1) infection (Cutrell et al., 2004). Abacavir
hypersensitivity syndrome (AHS) manifests systemically as
a combination of fever, rash, malaise, nausea, vomiting, and di-
arrhea and has even been associated with death in rechallenged
individuals (Hetherington et al., 2001). This constellation of
symptoms has some of the features of a graft versus host-like
cellular reaction. Indeed, there is strong evidence for an immuno-
logical basis of AHS reflected in the presence of infiltrating CD8+
T cells in the skin of patients with a rash (Phillips et al., 2002) and
the induction of elevated tumor necrosis factor-a (TNFa) and in-
terferon-g (IFNg) in patient whole blood and/or mononuclear
cells exposed to abacavir in vitro (Martin et al., 2007). Patients
who have experienced AHS also have more active nonspecific
cytokine production by T cells from peripheral blood (King
et al., 2005). A cellular immune reaction to abacavir is further
supported by the specificity of positive skin-patch tests for de-
layed-type hypersensitivity in patients with AHS (Phillips et al.,
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HLA Class I-Associated Drug Hypersensitivity2005). The association of AHS with the well-defined 57.1 major
histocompatibility complex (MHC) haplotype encoding the
MHC class I allotype (MHC-I), HLA-B*5701, is very strong (He-
therington et al., 2002; Mallal et al., 2002; Martin et al., 2004), es-
pecially when AHS is rigorously defined (Mallal et al., 2002; Mallal
et al., 2008; Martin et al., 2004). Thus, for immunologically con-
firmed AHS in the PREDICT-1 clinical trial, HLA-B*5701 was as-
sociated with a positive predictive value of 47.9% and a negative
predictive value of 100% (Mallal et al., 2008). The prevalence of
AHS varies according to the genetic background of the popula-
tion, probably because of ethnic variation in the phenotypic
frequency of HLA-B*5701 in some populations (Hughes et al.,
2004a). For instance AHS is less common in African Americans,
who are known to have higher frequency of HLA-B*5801, HLA-
B*5702, and HLA-B*5703 subtypes and a correspondingly lower
frequency of HLA-B*5701 than patients of European descent
(Hughes et al., 2004a). Some population differences in the
degree of association between AHS and HLA-B*5701 may arise
because reliance upon the clinical definition of AHS leads to
overassignment of the syndrome, thus confounding the associ-
ation with HLA-B*5701, especially where this allotype is present
at a low frequency (Hetherington et al., 2002; Mallal et al., 2008;
Martin et al., 2004; Sun et al., 2007). Accordingly, it is an
acknowledged best practice and is cost effective to carry out
HLA-B*5701 genotyping to prevent abacavir hypersensitivity
(Hughes et al., 2004b).
The mechanism of abacavir-induced hypersensitivity and the
basis for its association with HLA-B*5701 remain unknown but
are likely to be important in understanding the basis of other
MHC-I-associated disorders such as ankylosing spondylitis
(HLA-B27), Behc¸et’s disease (HLA-B51), and birdshot retinopa-
thy (HLA-A29). Abacavir is a prodrug that is converted to the
active compound, leading us to hypothesize that this process
may create a neoantigen that triggers CD8+ T cell immunity in
HLA-B*5701-positive individuals.
RESULTS
Abacavir-Specific, HLA-B*5701-Restricted CD8+ T
Responses in Patients with AHS
The peripheral-blood mononuclear cells (PBMCs) from two HIV-
1-infected patients with a history of AHS and who were HLA-
B*5701-positive, were stimulated with abacavir (10 mg/mL) for
11 to 14 days in vitro to test our hypothesis. This is the optimal
culture period for expansion of alloreactive and antigen-specific
memory CD8+ T cells in cultures that are supplemented with
Interleukin-2 (IL-2). At the completion of the culture period, the
expanded T cells were restimulated for 6 hr in the presence
and absence of abacavir with the HLA-B*5701-transfected,
MHC-I-deficient B lymphoblastoid cell line C1R as antigen-pre-
senting cells (APCs). Responding T cells were then examined for
their phenotype and the accumulation of intracellular cytokines
(as depicted schematically in Figure S1 available online).
CD8+ T cells from patients with AHS proliferated in response to
abacavir over 13 days and were specifically activated to produce
IFNg and TNFa, in the restimulation phase of the assay (Figure 1).
Notably, it was the CD8+ T cells that responded by making cyto-
kines, whereas the CD4+ T cells were not activated under the
same conditions. Similar results were obtained when autologousPBMCs were used as APCs (not shown). These findings raised
the likelihood that abacavir-specific CD8+ T cells play a key
role in the pathogenesis of AHS.
Abacavir-Specific Responses Can Be Primed In Vitro
in Healthy Normal Donors
Expansion of abacavir-specific CD8+ T cells from HIV-1-infected
patients with AHS was comparable to the expansion observed
for Epstein-Barr virus (EBV)-specific memory T cells or alloge-
neic stimulator cells (Mifsud et al., 2008), suggesting proliferation
of a memory cell population. This was confirmed by ex vivo
elispot studies on blood from patients with abacavir hypersensi-
tivity syndrome in which abacavir-specific, IFNg-producing cells
were detected with frequencies of up to 700 spots per 106
PBMCs (Figure S2). In contrast to the presence of memory T
cells in the circulation of abacavir-hypersensitive patients, we
did not detect abacavir-specific IFNg-producing cells in ex vivo
Elispot analyses of PBMCs from abacavir-naive normal HLA-
B*5701-positive blood donors. However, we also examined
T cell responses from abacavir-naive, HLA-B*5701-positive
blood donors after in vitro stimulation for 11–14 days by using
the same protocol as in HIV-1-infected patients. CD8+ T cells
from these healthy individuals also proliferated in vitro and
were specifically activated by abacavir to make IFNg and
TNFa (Figure 2A) over a pharmacological range of abacavir
Figure 1. CD8+ T Cells from Abacavir-Hypersensitive Patients with
HIV-1 Proliferate and Produce Cytokines in Response to Abacavir
Stimulation In Vitro
Flow-cytometry histograms of lymphocyte intracellular staining for IFNg after
abacavir stimulation. PBMCs from two HIV-1-infected patients with a history
of AHS were stimulated with abacavir for 11 to 14 days in vitro after which
the expanded T cells were then restimulated for 6 hr with the transfected lym-
phoblastoid cell line C1R expressing HLA-B*5701 in the presence (+) or ab-
sence () of abacavir (10 mg/mL). Cells were permeabilized and stained for in-
tracellular IFNg (y axis) and CD8 (x axis). Cells were gated as live lymphocytes.
The percentage of total gated lymphocytes is shown in each quadrant.Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc. 823
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HLA Class I-Associated Drug HypersensitivityFigure 2. CD8+ T Cells from HLA-B*5701-Positive Healthy Donors Specifically Proliferate and Make Cytokines in Response to Abacavir
(A) Flow-cytometry histograms of T cell intracellular staining for TNFa (left panels) and IFNg (right panels) after abacavir stimulation. PBMCs from two healthy,
HLA-B*5701-positive blood donors were stimulated with abacavir for 11 to 14 days in vitro after which the expanded T cells were then restimulated for 6 hr in824 Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc.
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HLA Class I-Associated Drug Hypersensitivityconcentrations (0.5-10 mg/mL or 1.8-36 mM), (Figure 2B). Exten-
sive washing of the APC after loading with abacavir preserved T
cell recognition, demonstrating that the response was APC de-
pendent and not a direct interaction between the T cell and the
drug. Abacavir-reactive CD8+ T cells from normal HLA-B*5701-
positive donors were also cytotoxic (Figure 2C). Importantly,
these responses were only observed in HLA-B*5701-positive in-
dividuals and could not be induced in individuals with any of the
other MHC-I backgrounds we tested (Figures 2C and 2D). None-
theless, EBV-specific CD8+ T cell responses were readily elicited
in HLA-B*5701-negative donors when a cocktail of known viral
peptides was used to restimulate the T cells (right panel,
Figure 2D). Abacavir-specific CD8+ T cells were not activated
by C1R.B57 loaded with a peptide derived from an EBV latent
membrane protein (LMP), IALYLQQNW (IALY) (Duraiswamy
et al., 2003) (not shown).
CD8+ T responses within each individual were entirely re-
stricted by the HLA-B*5701 allotype despite expression of non-
HLA-B*5701 MHC-I allotypes in these donors, (Figure 2E and
not shown). Thus, abacavir-reactive T cells from three different
donors were rechallenged with abacavir-loaded APCs express-
ing their individual MHC-I allotypes (e.g., for donor 1, HLA A2,
HLA A29, and HLA B57). T cell recognition of abacavir occurred
only when the cells were stimulated with HLA-B*5701-postive
APCs, (Figure 2E, randomized-block ANOVA p < 0.001).
In summary, abacavir-specific CD8+ T responses were
uniquely HLA-B*5701 restricted in HLA-B*5701- positive individ-
uals, and these responses could not be elicited in HLA-B*5701-
negative donors expressing seven common HLA-A allotypes
(HLA-A1, 2, 3, 11, 24, 29, and 68) and nine common HLA-B allo-
types (HLA-B7, 8, 18, 27, 35, 44, 45, 65, and 62). Moreover, aba-
cavir-specific, HLA-B*5701-restricted CD8+ T cells did not react
with abacavir-loaded APCs expressing 11 different allogeneic
MHC-I allotypes (not shown). Thus HLA-B*5701 restriction isa defining feature of abacavir-specific T cells isolated from aba-
cavir-naive individuals. Abacavir-specific CD8+ T cells interacted
conventionally with HLA-B*5701 because cytokine responses
were partially blocked by addition of a Bw4, HLA-B*5701-
reactive mAb, but not when the non-HLA-B*5701-reactive Bw6
mAb was added to the T cell cultures (Figure 2F).
We observed that in vitro cultures from patients with AHS gen-
erated a greater proportion of specific CD8+ T cells than similar
cultures from naive donors, consistent with CD8+ T cell memory
in the patients. Nonetheless, abacavir-specific T cells from both
groups were exclusively CD8+, HLA-B*5701-restricted, pro-
duced TNFa and IFNg, and were sensitive to abacavir over
a dose-response range that includes the serum concentration
of abacavir in treated patients. We conclude that the abacavir-
specific, HLA-B*5701-restricted CD8+ T cells generated in nor-
mal blood donors are similar in their specificity and nature to
the abacavir-reactive T cells detected in patients with AHS.
Therefore, we used responses from normal HLA-B*5701-posi-
tive donors to probe the biology and specificity of these abaca-
vir-specific responses.
Abacavir Responses Require the Conventional MHC-I
Antigen-Presentation Pathway
In the MHC-I-restricted antigen-presentation pathway, endoge-
nous peptide ligands are created in the cytoplasm by proteolysis
and then imported into the endoplasmic reticulum by the trans-
porter associated with antigen presentation (TAP) (McCluskey
et al., 2004) where peptide loading is optimized by the chaper-
one, tapasin (Williams et al., 2002b). Functional loss of either
TAP or tapasin leads to defective peptide loading and impaired
antigen presentation (Williams et al., 2002a). However, the
MHC-I antigen-presentation pathway can be bypassed by the
addition of exogenous peptide ligands to either living or alde-
hyde-fixed APCs through direct loading of ligand-receptivethe presence or absence of abacavir (10 mg/mL) with the transfected lymphoblastoid cell line C1R expressing HLA-B*5701. Cells were permeabilized and stained
for intracellular cytokine (y axis) and either CD8 (x axis, upper panels) or CD4 (x axis, lower panels). Cells were gated as live lymphocytes with percentages shown
in each quadrant. The number of abacavir-specific, cytokine-producing T cells could be enriched by iterative in vitro restimulation in the presence of IL-2, but
many cultures undergo exhaustion after 3 to 6 weeks in culture. However, in some donors the proportion of cytokine-producing T cells can be enriched to >
70% abacavir-specificity over 4 weeks in culture.
(B) Dose dependence of abacavir-specific CD8+ T cell responses in HLA-B*5701-positive blood donors determined by the percentage of IFNg-producing T cells
detected at the end of the in vitro stimulation period as described above. Figure depicts the mean ± standard error of the mean (SEM) of abacavir-specific CD8 T
cells elicited at each concentration of abacavir. Data are representative of three independent experiments on three different donors.
(C) T cells were first expanded from an HLA B57+ and two B57 blood donors in the presence of abacavir. The expanded polyclonal T cells were then tested in
a 51chromium release assay for cytotoxicity of autologous PHA blast target cells loaded with abacavir. Only T cells from the HLA B57+ donor lysed the abacavir-
loaded PHA blast cells. Although abacavir-specific T cells cannot be cultured from PBMCs in non-B*5701 donors, the same number of viable T cells was added to
the 51Cr-labelled target cells in all cases. We assume that the viable T cells cultured from PBMCs in non-B*5701 donors are nonspecifically expanded in the pres-
ence of IL-2 in the cultures. There was negligible (<1%) cytotoxicity of PHA blasts in the absence of abacavir (not shown). Data represent the mean percentage of
specific lysis ± SEM; p < 0.02 determined with a Student’s t test.
(D) Abacavir-specific CD8+ T cell responses are elicited in HLA-B*5701-positive but not HLA-B*5701-negative donors. PBMCs from HLA-B*5701-positive (Pos)
and -negative (Neg) blood donors were stimulated with abacavir as described above, and the responding CD8+ T cells (IFNg+) are shown as a percentage of total
gated lymphocytes (left histogram). CD8+ T cells from HLA-B*5701-positive and -negative donors were also expanded by a cocktail of cognate Epstein-Barr viral
peptides and then incubated with autologous APC loaded with the same peptides. Responses show the responding IFNg+ CD8+ T cells as a percentage of total
gated lymphocytes (right histogram). Data represent the mean abacavir-specific CD8 T cells ± SEM in each cohort. p < 0.0005 determined with a Student’s
pairwise t test in a two-tailed analysis.
(E) Abacavir-specific T cells expanded in vitro from three B57+ individuals as described above were rechallenged with a panel of abacavir-pulsed (10 mg/mL) cell
lines, either 721.221 or C1R, expressing the individual HLA-A and HLA-B allotypes expressed by each subject. The number of responding IFNg+ CD8+ T cells with
each APC is shown as a percentage of total gated lymphocytes.
(F) Activation of preformed abacavir-specific T cells by HLA-B*5701-positive APC was blocked by an anti-Bw4 monoclonal antibody (5 mg/mL) reactive with a con-
formational epitope located on the alpha-1 helix of HLA-B*5701 (left histograms). Blocking with the control non-HLA-B*5701-reactive monoclonal antibody anti-
Bw6 (right histograms). The figure shows the mean ± SEM of the percentage of responding IFNg+ CD8+ T cells as a proportion of total gated lymphocytes in three
independent experiments; p < 0.03 determined with a Student’s pairwise t test in a one-tailed analysis.Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc. 825
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HLA Class I-Associated Drug HypersensitivityFigure 3. Recognition of Abacavir by HLA B*5701-Restricted, CD8+ T Cells Requires Processing by APCs and Is TAP Dependent and Tapasin
Dependent
(A) Antigen-specific T cells recognizing the HLA-B*5701-restricted viral peptide IALY (open boxes) or abacavir (closed boxes) were used to probe MHC-I recog-
nition on unfixed (fixation) and aldehyde-fixed (fixation +) APCs. After washing of the APCs, they were loaded with abacavir (10 mg/mL) or synthetic viral peptide
(IALY, 1 mg/mL) and washed twice prior to a 2 hr incubation with specific CD8+ T cells followed by addition of BFA and intracellular cytokine staining 4 hr later.
Responses were compared in the presence (+) and absence () of antigen and shown as responding CD8+ T cells as a percentage of gated lymphocytes.
(B) Abacavir-specific CD8+ T cells were generated in four independent HLA-B*5701-positive donors and tested for abacavir recognition on normal HLA-B*5701-
positive APC (C1R.B57) and HLA-B*5701-positive APCs expressing the viral TAP-inhibitor ICP47 (C1R.B57.ICP47). Responses were assayed in the presence
(gray histograms) and absence (filled and open histograms) of abacavir (10 mg/mL) (upper panel). Surface expression of HLA-B*5701 was reduced 10-fold or
more on ICP47 transfectants (not shown). For each donor, CD8+ T cell responses were also generated toward the EBV peptide IALY and tested on the
same APC but in the presence (gray histograms) and absence (filled and open histograms) of the IALY peptide (10 mg /mL) (lower panel). Responses show
the responding IFNg+ CD8+ T cells as a percentage of total gated lymphocytes.
(C) HLA-B*5701-restricted, abacavir-specific CD8+ T cells were assayed for abacavir presentation in the presence (open boxes) or absence (closed boxes) of the
drug on APC that included the tapasin-deficient parental cell line 721.220 (220), 721.220 transfected with a human tapasin gene (220.hTsn), 721.220 expressing
HLA-B*5701 (220.B57), and 721.220 expressing human tapasin and HLA-B*5701 genes (220.hTsn.B57). Intracellular cytokine staining was carried out as de-
scribed in the Experimental Procedures. Responses show the responding IFNg+ CD8+ T cells as a percentage of total gated lymphocytes.MHC-I molecules on the cell surface. Such complexes are capa-
ble of recognition by antigen-specific T cells (Figure 3A). How-
ever, when abacavir was added to aldehyde-fixed, HLA-
B*5701-positive APCs, it did not reconstitute a ligand that could
stimulate abacavir-specific CD8+ T cells (Figure 3A), indicating
a need for live APCs to mediate intracellular processing or mod-
ification of the drug to create a ligand (Figure 3A). This finding was
reproducible in multiple experiments (n = 7) and statistically sig-
nificant (p < 0.001, Tukey HSD multiple comparison following log-
arithmic transformation of the data). Mutant HLA-B*5701-posi-
tive APCs in which TAP function was impaired by coexpression
of the viral TAP inhibitor ICP47 also did not present abacavir826 Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc.to specific CD8+ T cells generated in four different donors
(Figure 3B, upper panel). Exogenous loading of TAP-blocked
APC with a HLA-B*5701-restricted EBV peptide resulted in effi-
cient recognition by specific antiviral CD8+ T cells in the same
donors (Figure 3B, lower panel). Similarly, presentation of aba-
cavir was substantially reduced by the mutant tapasin-deficient
cell line 721.220 expressing HLA-B*5701 (Figure 3C). When
tapasin expression was restored in these cells by gene transfec-
tion, presentation of abacavir was also restored (Figure 3C). Pre-
sentation of abacavir to CD8+ T cells was also impaired by pre-
treatment of APC with the antifungal agent Brefeldin A, which
disrupts egress of newly synthesized and antigen-loaded
Immunity
HLA Class I-Associated Drug HypersensitivityMHC-I molecules from the endoplasmic reticulum to the cell sur-
face (not shown).
Taken together, these findings indicated that abacavir recog-
nition depends upon the conventional MHC-I antigen-presenta-
tion pathway and demonstrate that the unmodified prodrug is
insufficient to form a T cell ligand by direct cell-surface MHC-I
loading.
Specificity of Abacavir Recognition Maps
to the MHC-I-Binding Cleft
HLA-B*5701 is part of the serologically defined HLA-B17 allo-
typic family that includes naturally occurring variants HLA-
B*5702 and HLA-B*5801, which differ from HLA-B*5701 by
Figure 4. Abacavir-Specific CD8+ T Cells
Are Restricted by HLA-B*5701 and Not
HLA-B*5702 or HLA-B*5801
(A) Abacavir-specific T cells were raised in vitro
from a HLA-B*5701-positive donor and then re-
stimulated with human lymphoblastoid cell lines
expressing HLA-B*5701, HLA-B*5702, or HLA-
B*5801 in the presence (upper histograms) or ab-
sence (lower histograms) of abacavir (10 mg/mL).
Flow histograms of gated lymphocytes are shown
stained for intracellular IFNg (y axis) and CD8 (x
axis). The percentage of responding IFNg+ CD8+
T cells as a fraction of total gated lymphocytes is
shown in the upper-right-hand quadrants. Differ-
ences between the peptide-binding clefts of
HLA-B*5701, HLA-B*5702, and HLA-B*5801 are
indicated with filled circles, and the amino acid
substitutions from HLA-B*5701 are given above
each illustration.
(B) Abacavir-specific T cells were raised in vitro
from six independent HLA-B*5701-positive do-
nors and used to probe abacavir presentation by
APCs expressing HLA-B*5701, HLA-B*5702, or
HLA-B*5801. T cell responses were assayed after
stimulation in the absence of abacavir (B*5701,
B*5702, and B*5801) and in the presence of aba-
cavir (B*5701, B*5702, and B*5801+abacavir) (up-
per panel). Donor CD8+ T cells were also raised
in vitro against the EBV viral peptide IALY and
assayed for intracellular IFNg after stimulation in
the absence of peptide (B*5701, B*5702, and
B*5801) and in the presence of IALY 10 mg/mL
peptide (B*5701, B*5702, and B*5801+IALY)
(lower panel). Data from each donor are shown
as individual shaded histograms indicating the re-
sponding IFNg+ CD8+ T cells as a percentage of
total gated lymphocytes.
only three and four amino acids, respec-
tively (Figure 4A). Indeed, these closely re-
lated MHC-I allotypes have significant
overlap in their peptide repertoire (Barber
et al., 1997), and many virus-specific T
cells are crossreactive with all three
MHCp complexes (Duraiswamy et al.,
2003). However, abacavir-loaded lym-
phoblastoid cell lines expressing these
allotypes did not stimulate polyclonal
abacavir-specific, HLA-B*5701-restricted
CD8+ T cells from six independent donors (Figures 4A and 4B).
Nonetheless, in four of these donors, there was crossreactivity
of HLA-B*5701-restricted antiviral CD8+ T cells on peptide-
loaded HLA-B*5702 and HLA-B*5801 APCs (Figure 4B). The mu-
tations that distinguish HLA-B*5702 and HLA-B*5801 from HLA-
B*5701 are predominantly located in the antigen-binding cleft
(Figure 4A). Notably, HLA-B*5801 differs at residues 97 and
103 as well as residues 45 and 46, which form the B pocket an-
chor site. In contrast, HLA-B*5702 differs at position 156 and
residues 114 and 116, the latter of which forms the F pocket an-
chor site (Figure 4A). Accordingly, the failure of HLA-B*5801 and
HLA-B*5702 to stimulate CD8+ T cells suggests the abacavir-re-
lated ligand is either presented in an altered conformation or isImmunity 28, 822–832, June 2008 ª2008 Elsevier Inc. 827
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HLA Class I-Associated Drug HypersensitivityFigure 5. Fine Specificity of Abacavir-Specific CD8+ T Cells Determined by the Antigen-Binding F Pocket
Abacavir-specific T cells were raised in vitro from a HLA-B*5701-positive donor and then restimulated with the C1R cell lines expressing HLA-B*5701, HLA-
B*5703, the HLA-B*5703 back mutant 114Asp/Asn, or the HLA-B*5703 back mutant 116Ser/Tyr. Flow histograms of gated lymphocytes are shown stained
for intracellular I IFNg (y axis) and CD8 (x axis). The percentage of responding IFNg+ CD8+ T cells as a fraction of total gated lymphocytes is shown in the upper-
right-hand quadrants. Differences between the peptide-binding clefts of HLA-B*5701, HLA-B*5703, and HLA-B*5703 back mutants are indicated with filled cir-
cles, and the amino acid substitutions from B*5701 are given above each illustration.not presented at all by these MHC-I allotypes because of the al-
tered chemical structure of their antigen-binding cleft. The latter
seems more likely, given the lack of any association between
AHS and these or any other MHC-I allotypes.
Despite the overlap in peptide repertoire of the B17 allotypic
group, HLA-B*5701 prefers a lysine residue as the optimal resi-
due of the bound peptide at position 3, whereas HLA-B*5702
prefers an aspartic acid in this position (Barber et al., 1997).
Hence, the amino acid substitutions between HLA-B*5701 and
HLA-B*5702 at positions 114 (D/N), 116 (S/Y), and 156
(L/R) could influence abacavir recognition via selection of
amino acids at P3, the C terminus, or both. To determine whether
the loss of abacavir presentation by HLA-B*5702 could arise
entirely from the substitutions at 114 (D/N) and 116 (S/Y),
we made these two substitutions by site-directed mutagenesis,
thus creating the natural allotypic variant, HLA-B*5703. abaca-
vir-loaded C1R cells expressing the HLA-B*5703 molecule did
not stimulate abacavir-specific CD8+ T cells, indicating that sub-
stitution of F pocket residues 114 and 116 was sufficient to im-
pair presentation of the abacavir-related ligand (Figure 5, second
panel). The impact of individually changing residues 114 and 116
was then examined. Substitution of residue 114 from a negatively
charged aspartate in HLA-B*5701 to a neutrally charged aspar-
agine in HLA-B*5703 (D/N) resulted in a > 50% reduction in
the number of IFNg-producing CD8+ T cells and lower levels of
IFNg production by the remaining responding cells (Figure 5,
third panel). Substitution of position 116, from a polar serine in
HLA-B*5701 to the aromatic tyrosine residue of HLA-B*5703
(S/Y), completely abrogated recognition by abacavir-specific
CD8+ T cells (Figure 5, fourth panel). Position 116 is particularly828 Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc.important in determining the structure of the F pocket and thus
controls selection of the dominant anchor residue at the C termi-
nus of bound peptides (Gomez et al., 2006; Zernich et al., 2004).
Distinct Architecture of the HLA-B*5701 and HLA-
B*5703 F Pockets Specifies Antigen Selection
The repertoire of peptides bound by HLA- HLA-B*5701, HLA-
B*5702, and HLA-B*5801 allotypes share a preference for tryp-
tophan or a phenylalanine at position 9 in the F pocket (Barber
et al., 1997). However, only HLA-B*5701 is reported to also ac-
commodate a tyrosine in this position, indicating that the F
pocket polymorphism results in selection of a different subset
of endogenous ligands by HLA-B*5701 (Barber et al., 1997) as
observed for other MHC-I allotypes (Kubo et al., 1998; Ramos
et al., 2002; Zernich et al., 2004). To understand the impact of
the F pocket polymorphism better, we directly solved the X-ray
crystallographic structure of HLA-B*5701 complexed to a self-
peptide (LSSPVTKSF, LF9) (see Supplemental Data) and com-
pared this to the published structure of HLA-B*5703 bound to
an HIV-1 peptide (KAFSPEVIPMF, KF11) (Stewart-Jones et al.,
2005). The structure of the HLA-B*5701-LF9 complex confirmed
that the two critical anchor residues at positions P2 (Ser) and P9
(Phe) bind in the B and F pockets of HLA-B*5701, respectively
(not shown and Figure 6). Although HLA-B*5701 and HLA-
B*5703 are complexed to two different peptides, the KF11
bound to HLA-B*5703 and the LF9 bound to HLA-B*5701 both
have a Phe at the C terminus. Moreover, in the structures of
HLA-B*5703 complexed with three different peptides, there
was very little difference in the side-chain conformations of the
F pocket amino acids. However, the H bonding of the Asp114
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chain of the F pocket residue 116 in HLA-B*5701 (Figure 6A),
suggests that substitution of this residue to a large aromatic
tyrosine found in HLA-B*5703 (Figure 6B) may abolish or alter
binding of some peptides. Overall, the F pocket of HLA-B*5701
is more electronegative than in HLA-B*5703 (Figures 6C and
6D). These findings are consistent with the changes in F pocket
architecture that alter immune recognition and peptide repertoire
as observed between other closely related MHC-I allotypes
(Hulsmeyer et al., 2002; Zernich et al., 2004).
Taken together, the findings indicate exquisite fine specificity
in the HLA restriction of abacavir-specific CD8+ T cell responses.
This specificity can be mapped to the structure of the F pocket of
the MHC-1 antigen-binding cleft, typical of many peptide-spe-
cific CD8+ T cell responses. Moreover, in addition to this HLA re-
striction, abacavir-reactive T cells did not react with three com-
pounds structurally related to abacavir, namely, didanosine,
carbovir, and guanosine (Figure S3).
DISCUSSION
When skin-patch testing is combined with clinical diagnosis, the
sensitivity of HLA-B*5701 testing in predicting AHS is 100%
Figure 6. Distinct Chemical Architectures and Electrostatic Poten-
tial Characterizes the F Pocket of HLA-B*5701 Compared with
HLA-B*5703
(A) The C-terminal residues of the self-peptide, LSSPVTKSF (LF9, purple), in
the F pocket of HLA-B*5701 are shown, PDB ID code 2RFX. The residues at
the polymorphic positions 114 and 116 are shown in gray.
(B) The C-terminal residues of the HIV-1 peptide, KAFSPEVIPMF (KF11,
purple), in the F pocket of HLA-B*5703 are shown. The residues at positions
114 and 116, which are the polymorphic residues, are shown in gray.
(C) Surface representation of the F pocket of HLA-B*5701 and (D) HLA-B*5703,
showing the electrostatics of the pocket (red, electronegative; blue, electro-
positive). The LF9 peptide is shown in purple. The F pocket is more electro-
negative in HLA-B*5701 compared to HLA-B*5703.and the specificity is 90%–100%, suggesting an exquisitely
controlled mechanism involving the HLA-B*5701 molecule itself.
Here we have shown that abacavir is highly immunogenic to
CD8+ T cells not only in patients with a history of AHS but also
in healthy, abacavir-naive HLA-B*5701-positive blood donors.
The stimulation of CD8+ T cells is abacavir specific and only
observed in individuals expressing HLA-B*5701. The T cells
are HLA-B*5701 restricted and expanded to high frequencies
(up to 25% of lymphocytes) after in vitro culture with IL-2. Abaca-
vir-specific CD8+ T cells secrete inflammatory mediators TNFa
and IFNg and are cytotoxic to abacavir-loaded APCs.
Our findings on the molecular mechanisms of abacavir presen-
tation show that this is linked to the classical MHC-I pathway and
shows fine specificity typical of most peptide antigens recognized
by T cells. Abacavir is also a prodrug that undergoes deamination
and phosphorylation to form an active drug,carbovir triphosphate
(Ray et al., 2002), providing an opportunity for reactive groups on
the drug to couple with enzyme side chains, or perhaps other cel-
lular proteins, creating a neo-self-antigen. In preliminary experi-
ments, we observed that abacavir-specific T cells did not react
against three related compounds, carbovir, didanosine, and gua-
nosine. The data implicate the 6-cyclopropylamino group on the
main guanosyl ring as a possible reactive site because all three
compounds lack this group whereas the primary amine group in
the abacavir structure is also present in guanosine and carbovir.
In other preliminary experiments, we have identified several frac-
tions eluted from abacavir-loaded, HLA-B*5701-positive cell lines
that have weak stimulatory activity when added back to abacavir-
free HLA-B*5701-positive cells (not shown). Therefore, we pro-
pose that a derivative of abacavir forms a conjugate with one or
more self-peptides that are uniquely presented by HLA-B*5701.
Subtle alterations to self-peptides can be highly immunogenic, in-
cluding accidental modifications that occur during peptide syn-
thesis (Chen et al., 1996; Purcell et al., 1998), posttranslational
modifications (Henderson et al., 2007; Molberg et al., 1998;
Skipper et al., 1996), glycosylation, and chemical haptenation
(Haurum et al., 1994; Mizushima et al., 1985).
The relationship between the in vitro responses observed in
CD8+ T cells and the development of AHS in vivo is compelling.
CD8+ T cells are abundant in the skin biopsies of patients with
AHS and a rash. Skin-patch testing recalls a delayed-type-
hypersensitivity reaction typical of prior cellular immunity. The
time of onset of AHS after initiation of drug therapy (10–40
days) is consistent with the time needed to prime naive T cells.
Moreover, the lack of any abacavir recognition using HLA-
B*5702, HLA-B*5703, and HLA-B*5801 APCs suggests a failure
of antigen presentation by these allotypes consistent with the
lower prevalence of AHS in populations where HLA-B*5702,
HLA-B*5703, or HLA-B*5801 are more common than HLA-
B*5701. The detection of abacavir-reactive CD8+ T cells from
drug-naive, healthy normals suggests that HIV-1 infection does
not play a specific role in AHS. However, the overall immune
activation in HIV infection has been defined as a general risk
factor for drug hypersensitivity and may amplify the likelihood
of systemic reactions.
The expansion of T cell reactivities in vitro is generally ob-
served where antigens have high precursor frequencies resulting
from prior antigen exposure, or where very high precursor fre-
quencies exist in the naive repertoire, such as T cells recognizingImmunity 28, 822–832, June 2008 ª2008 Elsevier Inc. 829
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induction of abacavir-specific CD8+ T cells in abacavir-naive,
healthy blood donors is surprising. Moreover, many MHC-I spec-
ificities require T helper activity for their initial expansion and ef-
fector functions. We have not found any evidence that abacavir-
specific CD8+ T cells in abacavir-naive donors are drawn from
a crossreactive antiviral memory population. TCR Vb usage of
abacavir-specific CD8+ T cells is polyclonal and reactivity toward
known HLA-B*5701-restricted viral peptides was negative (not
shown). We consider that the expansion of these cells in vitro
must reflect the potent immunogenicity of this drug. One reason
for this may be that abacavir might have intrinsic costimulatory
activity because it is known to induce changes in APC that might
in turn help prime CD8+ T cells in vitro overcoming the lack of
a memory population in naive individuals (Martin et al., 2007).
Our findings demonstrate that abacavir hypersensitivity is an
MHC-I-restricted cellular hypersensitivity mediated by CD8+ T
cell activation, in contrast to the more common nickel hypersen-
sitivity and occupational lung disease, Berylliosis, which are
MHC-II linked and elicit CD4+ T cell delayed-type-hypersensitiv-
ity responses (Lombardi et al., 2001; Richeldi et al., 1993). The
high frequency of reactive T cells observed in nickel hypersensi-
tivity occurs because solvent-exposed amino acids on the MHC-
peptide and TCR proteins jointly coordinate the nickel ions (Lu
et al., 2003), directly linking the TCR-MHC-peptide-like weak
superantigens (Gamerdinger et al., 2003). T cell responses to be-
ryllium (Be++) are exquisitely dependent upon glutamic acid (Glu)
at position 69 in the HLA-DP b-chain, also suggesting specific
metal coordination on a solvent-exposed interface involved in
TCR ligation (Lombardi et al., 2001; Richeldi et al., 1993). Unlike
the CD4+ T cell hypersensitivity to Ni++ and Be++, the fine spec-
ificity of abacavir recognition maps to the F pocket of HLA-
B*5701 and is not accessible for TCR interaction and yet is cru-
cial to the presentation of the abacavir ligand. The critical residue
at position 116 that controls the difference in antigen presenta-
tion by HLA-B*5701 (Ser) and HLA-B*5703 (Tyr) could exert its
influence on peptide binding through subtle differences in ac-
commodation of C-terminal peptide side chains. It is also possi-
ble that abacavir itself, or a metabolite, is accommodated in the F
pocket and that the smaller serine side chain is necessary for this
binding. Alternatively, abacavir may be conjugated to a solvent-
exposed region of an endogenously bound peptide, creating
a haptenated self-peptide. Our study does not resolve this issue,
nor can we say whether abacavir is bound covalently or nonco-
valently to an endogenous peptide ligand. Importantly, however,
dramatic functional differences in HIV immunity are also ob-
served in patients with HLA-B*5701 versus those with HLA-
B*5703. Patients with these MHC-I allotypes make a dominant
CTL response to the same HIV-1 Gag epitope, but the T cell rep-
ertoire and prevalence of HIV-specific epitope escape mutants
differ dramatically in the two immune responses (Gillespie
et al., 2006; Yu et al., 2007). Presumably, the conformation of
the HIV peptide must be different in these two MHC-I allotypes.
It is also possible that the differences in the F pocket of
HLA-B*5701 and HLA-B*5703 could alter the pathway of peptide
acquisition as observed between the tapasin-dependent
HLA-B*4402 (Asp116) and tapasin-independent HLA-B*4405
(Tyr116) molecules (Zernich et al., 2004). Although these allo-
types only differ at position 116, they have different peptide rep-830 Immunity 28, 822–832, June 2008 ª2008 Elsevier Inc.ertoires and different modes of peptide acquisition that make
them differentially resistant to viral evasion (Zernich et al., 2004).
The exquisite fine specificity of abacavir presentation coupled
with the strong association of HLA-B*5701 with AHS has impor-
tant implications for understanding other MHC-I associations
with disease. Strong associations between particular MHC-I al-
lotypes and protection from infection have been difficult to dem-
onstrate. There are only a few examples, such as HIV-1 infection
(Carrington and O’Brien, 2003), where the small viral genome
and prolonged nature of the infection are probably crucial to
revealing progressor and nonprogressor MHC-I associations.
Another is protection against cerebral malaria associated with
HLA-B53 (Hill et al., 1992). None of these associations are partic-
ularly strong compared with diagnostically useful strong associ-
ation of HLA-B27 with ankylosing spondylitis or HLA-A29 and
Birdshot retinopathy (Margulies et al., 2008). We propose that
strong protective MHC-I phenotypes are not easily observed in
immunity to infections because of the large number of potential
peptide ligands available as signatures of pathogen recognition
and the diversity of potential MHC-I allotypes expressed in the
host (up to six distinct MHC-I allotypes). The mechanism of
AHS suggests that two layers of specificity operate to single
out HLA-B*5701 as a genetic determinant of this drug hypersen-
sitivity. The first point of specificity occurs during drug targeting
of endogenous proteins or peptides to create a unique ligand(s).
This step is likely to considerably narrow the pool of potential
ligands available for host class I molecules. The second layer
of specificity occurs through selective binding and presentation
of one or more of these ligands by particular MHC-I molecules as
a result of the polymorphic nature of the antigen-binding cleft.
Perhaps the strong association of ankylosing spondylitis with
HLA-B27, Birdshot retinopathy with HLA-A29, or Behc¸et’s dis-
ease with HLA-B51 also reflects more than one layer of specific-
ity. Thus, pathogen-derived small molecules (or enzymes) may
interact with, or modify, specific peptides that are then subject
to further selection by particular MHC-I allotypes, creating path-
ogenic ligands of highly refined specificity.
Our findings explain the strong pharmacogenetic link between
HLAB*5701 and abacavir hypersensitivity syndrome. They also
point the way to understanding the basis for other HLA-linked
drug reactions and implicate T cells in the pathogenesis of sys-
temic reactions such as Stevens-Johnson syndrome. Further
understanding of these life-threatening reactions should allow
rational immunotherapeutic treatment with anti-T cells or
anti-cytokine reagents.
EXPERIMENTAL PROCEDURES
Clinical samples came from the HIV clinics of Royal Perth Hospital (Wellington
St., Perth, Western Australia) and St. Vincent’s Hospital (Sydney, Australia).
Normal blood donors were from the Australian Bone Marrow Donor Registry.
Institutional ethics approvals were obtained for use of all clinical material.
HLA-A and B loci were typed for each donor by DNA sequencing to obtain
four-digit high-resolution genotyping of class I alleles (Victorian Transplanta-
tion and Immunogenetics Service [VTIS], Victoria, Australia).
Cell Lines and Culture
Peripheral-blood samples were collected in heparinized vacutainer tubes and
PBMC were isolated via the standard Ficoll-Paque and density-gradient cen-
trifugation method. Single-gene MHC-I transfectants of the HLA-class I-defi-
cient lymphoblastoid cell lines C1R (Zemmour et al., 1992) or 721.221 (Shimizu
Immunity
HLA Class I-Associated Drug Hypersensitivityet al., 1988) were used as defined APCs to map HLA restriction of T cell re-
sponses at the conclusion of the period of in vitro stimulation with autologous
PBMCs. Transfection was carried out as previously described (Peh et al.,
1998; Zernich et al., 2004), or cell lines were obtained as gifts (Rajiv Khanna,
Queensland Institute of Medical Research). Culture conditions are described
in the Supplemental Data.
ICP47 and Tapasin Transfectants
C1R cells were transfected with a cDNA encoding the Herpes Simplex TAP in-
hibitor ICP47 by electroporation of plasmid DNA and drug selection of trans-
formants as described (Zernich et al., 2004). HLA-B*5701 expression was re-
duced by 10-fold or more in the presence of ICP47. A cDNA encoding HLA-
B*5701 was transfected into the tapasin-deficient cell line 721.220 as previ-
ously described (Zernich et al., 2004). Rescue of the impaired cell-surface ex-
pression of HLA-B*5701 (10- to 100-fold increase) was achieved by cotrans-
fection of a cDNA encoding the human tapasin gene (Zernich et al., 2004).
Expression of tapasin was confirmed by immunoblotting as previously de-
scribed (Peh et al., 1998).
Lymphocyte Stimulation and Intracellular Cytokine Staining
T cell cultures were generated from approximately 107 responder PBMCs
stimulated with 5 3 106 irradiated autologous PBMCs (Macdonald et al.,
2003). Abacavir (Glaxo Smith Kline, Ziagen tablets) was present throughout
the culture period at 10 mg/mL. Abacavir purity was confirmed by mass spec-
trometry (not shown). Culture medium was supplemented with 10 U/ml re-
combinant human IL-2 and changed every 2–3 days to maintain saturating
levels of nutrients and growth factors. On day 11–14, 2 3 105 responders
from T cell culture were harvested, washed, and then restimulated with 105 de-
fined APC (either autologous PBMCs or defined cell lines) in the presence and
absence of 10 mg/ml antigen resuspended in RPMI (peptide samples) or
RPMI + 10% fetal calf serum (abacavir samples). After incubating for 1 hr at
room temperature (RT), cells were washed twice in RPMI at 500 3 g (5 min,
RT) and resuspended in relevant media. After 2 hr of coincubation at 37C/5%
CO2, 10 mg/ml Brefeldin A (Sigma) was added for a further 4 hr. Responder
CD8+ T cells were stained with anti-CD8 CyChrome and anti-CD4 phycoery-
thrin (Becton Dickinson Biosciences, San Jose, CA), fixed with 1% paraformal-
dehyde (ProSciTech, Queensland, Australia) and permeabilized with 0.3% Sa-
ponin (Sigma) containing anti-IFNg FITC or anti-TNFaAPC (Becton Dickinson).
Samples were incubated at 4C, in the dark for at least 40 min. Cells were
washed and resuspended in 150 ml of PBS for analysis by flow cytometry within
48 hr. The percentage of gated lymphocytes producing IFNg was determined
by flow cytometry with FlowJo software (Tree Star Incorporated, CA). Abaca-
vir-specific T cell responses were generated independently for most experi-
ments and varied according to the particular responder and other variables
intrinsic to cellular immunology.
For mAb blocking studies, after addition of antigen, purified anti-Bw4 anti-
body (5 mg/mL) was added to APC, mixed with responder T cells, and the as-
say was carried out as described above. Fixation, 51chromium release assays,
and statistical methods are described in the Supplemental Data. Structural
methods are described elsewhere (Clements et al., 2002) with additional
methods, data collection, and refinement statistics provided in Table S1.
ACCESSION NUMBERS
The HLA-B*5701LSSPVTKSF structure has been deposited in the Protein Data
Bank under code 2RFX.
SUPPLEMENTAL DATA
Additional Experimental Procedures, three figures, and one table are available
at http://www.immunity.com/cgi/content/full/28/6/822/DC1/.
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